Impact of Incremental Delays in Appropriate Therapy on the Outcomes of Hospitalized Adult Patients with Gram-negative Bloodstream Infections: "Every day matters"
- PMID: 33112456
- DOI: 10.1002/phar.2446
Impact of Incremental Delays in Appropriate Therapy on the Outcomes of Hospitalized Adult Patients with Gram-negative Bloodstream Infections: "Every day matters"
Abstract
Background: Serious bloodstream infections (BSIs) are often caused by Gram-negative (GN) bacteria in hospitalized patients. Treatment of these infections has been further complicated by the continued rise and spread of drug-resistant pathogens, including carbapenem resistant (CR) strains of Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
Methods: This retrospective cohort analysis used real-world data from a large United States hospital-based database to examine the association between key clinical outcomes and different lengths of time to appropriate treatment between October 2010 and September 2015.
Results: Of 40,549 patients with GN-BSIs who were identified, 1117 (2.8%) had a CR GN-BSI. Overall, outcomes of hospitalized adult patients with GN-BSIs incrementally worsened the longer appropriate therapy was delayed. Patients with CR GN-BSIs had a median infection-associated length of stay (LOS) of 8, 9, 10, and 13 days, whereas patients with CS GN-BSIs had a median infection-associated LOS of 6, 7, 8, and 11 days for patients with days to appropriate therapy of 0, 1-2, 3-4, and ≥ 5 days, respectively. Among patients with CR GN-BSIs, the percentage of patients discharged home was 38%, 33%, 35%, and 31%, whereas in patients with CS GN-BSIs, the percentage of patients discharged home was 58%, 53%, 48%, and 43% for patients with days to appropriate therapy of 0, 1-2, 3-4, and ≥ 5 days, respectively.
Conclusion: The findings from this study highlight the clear need to deliver appropriate therapy more expeditiously in patients with CS and CR GN-BSIs.
Keywords: appropriate therapy; bloodstream infection; gram‐negative; real‐world evidence.
© 2020 Pharmacotherapy Publications, Inc.
Similar articles
-
Rectal culture could predict carbapenem-resistant organism bloodstream infection and reduce the mortality in haematological patients: A retrospective cohort study.J Glob Antimicrob Resist. 2024 Mar;36:96-104. doi: 10.1016/j.jgar.2023.12.007. Epub 2023 Dec 19. J Glob Antimicrob Resist. 2024. PMID: 38128727
-
The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.Int J Antimicrob Agents. 2021 Jun;57(6):106335. doi: 10.1016/j.ijantimicag.2021.106335. Epub 2021 Apr 7. Int J Antimicrob Agents. 2021. PMID: 33838223
-
Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.Front Cell Infect Microbiol. 2015 Feb 12;5:11. doi: 10.3389/fcimb.2015.00011. eCollection 2015. Front Cell Infect Microbiol. 2015. PMID: 25729741 Free PMC article.
-
The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies.BMC Infect Dis. 2021 Jun 9;21(1):545. doi: 10.1186/s12879-021-06253-x. BMC Infect Dis. 2021. PMID: 34107899 Free PMC article.
-
Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review.Antimicrob Resist Infect Control. 2019 Nov 4;8:170. doi: 10.1186/s13756-019-0624-1. eCollection 2019. Antimicrob Resist Infect Control. 2019. PMID: 31709047 Free PMC article.
Cited by
-
Clinical Characteristics and Prognosis Analysis of Acinetobacter baumannii Bloodstream Infection Based on Propensity Matching.Infect Drug Resist. 2022 Nov 30;15:6963-6974. doi: 10.2147/IDR.S387898. eCollection 2022. Infect Drug Resist. 2022. PMID: 36474906 Free PMC article.
-
Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa.J Antimicrob Chemother. 2024 Nov 4;79(11):2954-2964. doi: 10.1093/jac/dkae313. J Antimicrob Chemother. 2024. PMID: 39258877 Free PMC article.
-
Impact of a Laboratory-Developed Phenotypic Rapid Susceptibility Test Directly From Positive Blood Cultures on Time to Narrowest Effective Therapy in Patients With Gram-Negative Bacteremia: A Prospective Randomized Trial.Open Forum Infect Dis. 2022 Jul 22;9(7):ofac347. doi: 10.1093/ofid/ofac347. eCollection 2022 Jul. Open Forum Infect Dis. 2022. PMID: 35919072 Free PMC article.
-
Epidemiology and Economic Outcomes Associated with Timely versus Delayed Receipt of Appropriate Antibiotic Therapy among US Patients Hospitalized for Native Septic Arthritis: A Retrospective Cohort Study.Antibiotics (Basel). 2022 Dec 1;11(12):1732. doi: 10.3390/antibiotics11121732. Antibiotics (Basel). 2022. PMID: 36551387 Free PMC article.
-
Prevalence and molecular characterisation of multi-drug resistant ST11 hypervirulent Klebsiella pneumoniae in a teaching hospital.BMC Microbiol. 2025 Jun 6;25(1):352. doi: 10.1186/s12866-025-04052-x. BMC Microbiol. 2025. PMID: 40474116 Free PMC article.
References
-
- Cai B, Echols R, Magee G, et al. Prevalence of carbapenem-resistant Gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa. Open Forum Infect Dis 2017;4(3):1-7.
-
- Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49(1):1-45.
-
- Gniadek TJ, Carroll KC, Simner PJ. Carbapenem-resistant non-glucose-fermenting Gram-negative bacilli: the missing piece to the puzzle. J Clin Microbiol 2016;54(7):1700-10.
-
- Micek ST, Wunderink RG, Kollef MH, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care 2015;19(1):219-26.
-
- Coulter S, Roberts JA, Hajkowicz K, Halton K. The use of bloodstream infection mortality to measure the impact of antimicrobial stewardship interventions: assessing the evidence. Infect Dis Rep 2017;9(1):6849.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical